TransEnterix, now rebranded as Asensus Surgical, Inc., is a pioneering medical technology company dedicated to transforming surgical care through digital innovation and robotic-assisted systems. Founded with a vision to enhance minimally invasive surgery, the company integrates advanced robotics, machine vision, and artificial intelligence to empower surgeons with unprecedented precision, control, and insight.

At the core of Asensus Surgical’s offerings is the Senhance® Surgical System, a multi-port robotic platform that combines independent robotic arms, haptic feedback, infrared eye tracking, and reusable instruments to elevate surgical performance. Complementing this is the Intelligent Surgical Unit (ISU), an FDA-cleared technology that leverages augmented intelligence for enhanced camera control, marking a step forward in computer-assisted surgery.

Through strategic partnerships, including its collaboration with global medical leader KARL STORZ, Asensus Surgical is advancing the frontier of digital surgery. The company continues to innovate with next-generation platforms such as the Luna System, aiming to further streamline procedures, improve patient outcomes, and expand the possibilities of surgical robotics.

Recognized globally for its contributions to healthcare innovation, Asensus Surgical has earned multiple awards, including the Digital Health Award 2025, RBR50 Robotics Innovation Award 2025, and TIME’s Best Inventions of 2024. The company’s mission remains clear: to transform surgical care by combining human skill with intelligent technology, ultimately enabling safer, more efficient, and more effective surgeries worldwide.